...

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al.

【24h】

Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al.

机译：回复编辑的信：'患者中心护理的硬路：3月6个月的辅助化疗，患者III阶段结肠癌癌症？由P. Trendsz等。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2018年第8期|共3页
作者
Sobrero A.; Douillard J-Y;
展开▼
作者单位

IRCCS San Martino Hosp Dept Med Oncol Genoa Italy;

CMO ESMO Lugano Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al. [J] . Sobrero A., Douillard J-Y Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第8期

机译：回复编辑的信：'患者中心护理的硬路：3月6个月的辅助化疗，患者III阶段结肠癌癌症？由P. Trendsz等。
2. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? [J] . ASobrero, AGrothey, TIveson, Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第5期

机译：数据解释的硬路：3月6个月的辅助化疗为III阶段结肠癌患者？
3. Reply to the Letter to the Editor 'Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?' by Abali et al. [J] . Sugihara K., Yoshida M., Ishiguro M. Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第1期

机译：回复给编辑的信“不使用奥沙利铂的氟嘧啶类药物是否最适合主流III期结肠癌的辅助治疗？”由Abali等人撰写。
4. Adjuvant Chemotherapy Should Not Routinely Be Recommended to Patients with Stage II Colon Cancers that Manifest Microsatellite Instability [C] . Sigurdis Haraldsdottir, Richard M. Goldberg Gastrointestinal Cancers Symposium . 2014

机译：不应常规向患有阶段结肠癌的患者常规的辅助化学疗法，表明微卫星不稳定性
5. Adherence to adjuvant chemotherapy and post-treatment surveillance in a large community-based cohort of patients with colon cancer. [D] . Hu, Chung-Yuan. 2010

机译：在结肠癌患者的大型社区队列中坚持辅助化疗和治疗后监测。
6. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [O] . Thierry André, Timothy Iveson, Roberto Labianca, -1

机译：IDEA（国际辅助化疗持续时间评估）合作：III期试验的前瞻性联合分析研究针对III期结肠癌患者的FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月至6个月）方案的辅助治疗的持续时间的III期试验：试验设计与现状
7. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? [O] . A. Sobrero, A. Grothey, T. Iveson, 2018

机译：数据解释的硬路：3月6个月的辅助化疗为III期结肠癌患者？

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号